BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

AbbVie Acquires Capstan Therapeutics for $2.1B, Gaining In Vivo CAR-T Platform Targeting Autoimmune Diseases

by Roman Kasianov   •   June 30, 2025  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# Startups & Deals   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

AbbVie announced a definitive agreement to acquire Capstan Therapeutics for up to $2.1 billion in cash, gaining access to its targeted lipid nanoparticle (tLNP) platform for in vivo cell engineering and its lead candidate, CPTX2309. The platform enables mRNA delivery directly to CD8+ T cells to induce transient anti-CD19 CAR expression in vivo, aiming to deplete B cells and reset immune function in B cell-mediated autoimmune diseases.

#advertisement
How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning

Capstan Therapeutics Team; Source: CapstanTx

CPTX2309 is in Phase 1 development and does not require lymphodepletion or ex vivo cell manipulation. It uses Capstan’s hepatic de-targeting technology to selectively reprogram CD8+ cytotoxic T cells, which then act to eliminate autoreactive B cells in tissues and peripheral blood. This mechanism is intended to enable immune system rebalancing through depletion of pathogenic memory B cells and reconstitution with naïve populations.

See also: The Promise Of Cell Technologies In Immunotherapy

Founded in 2021, Capstan previously raised a $175M Series B in 2024 to advance its CellSeeker platform. The company’s targeted LNP system uses antibody-conjugated nanoparticles to deliver RNA payloads for in vivo cell programming. 

The transaction is subject to regulatory review under the Hart-Scott-Rodino Act. Capstan was advised by Centerview Partners and Cooley LLP. AbbVie did not disclose timelines for regulatory or commercial milestones related to CPTX2309.

Topics: Startups & Deals   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.